|Videos|June 16, 2017

Can New Antimalarials Be a Gamechanger in Endemic Countries?

Jeremy Burrows, DPhil, MA, explains how new antimalarials could change the game for countries where malaria is endemic.

Jeremy Burrows, DPhil, MA, Vice President, Head of Discovery, Medicines for Malaria Venture, Switzerland, explains how new antimalarials could change the game for countries where malaria is endemic.

Interview Transcript (slightly modified for readability)

“In the countries where malaria is endemic, these new treatment options are still incredibly important. First, because they will provide the treatment options of the future when the existing drugs fail because of resistance. Secondly, we have this ambition for elimination, eradication, and these new drugs, which are coming through the pipeline we hope will deliver the tools that will actually enable us to do that.”


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.